HBD-2 vs Mifamurtide
Head-to-head comparison of HBD-2 (Human Beta-Defensin 2) and Mifamurtide (Muramyl Tripeptide Phosphatidylethanolamine) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | HBD-2 | Mifamurtide |
|---|---|---|
| Category | Immune Support | Immune Support |
| Full Name | Human Beta-Defensin 2 | Muramyl Tripeptide Phosphatidylethanolamine |
| Molecular Weight | 4316 Da | N/A |
| Half-Life | Minutes to hours; protease-sensitive | 2-4 h |
| Amino Acids | 41 | N/A |
| Typical Dose | Research use only; no approved human dose | 2 mg/m2 |
| Route | Topical / Intranasal / Research parenteral | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 420 | 150 |
| Research Status | Pre-clinical | Clinical |
HBD-2 Benefits
- ✓broad-spectrum antimicrobial activity
- ✓epithelial barrier defense
- ✓innate immune modulation
- ✓anti-biofilm potential
Mifamurtide Benefits
- ✓macrophage-activation
- ✓innate-immune-signaling
- ✓immune-adjuvant-research
- ✓cytokine-response
HBD-2 Dosing
0.1–10 µM in vitro|1–5 mg/kg in animal models|No established human dose
Mifamurtide Dosing
2 mg/m2 IV|2x weekly for 12 weeks|then weekly for 24 weeks in approved regimens
HBD-2 Side Effects
- ⚠local irritation at high concentrations
- ⚠proteolytic instability
- ⚠potential pro-inflammatory signaling
Mifamurtide Side Effects
- ⚠fever/chills
- ⚠fatigue
- ⚠nausea
Research Overview
HBD-2
Human beta-defensin 2 has been studied extensively for direct microbicidal effects and for its role in shaping mucosal immunity. Preclinical work shows activity against Gram-negative and Gram-positive organisms, with additional effects on leukocyte recruitment and wound defense.
Mifamurtide
Mifamurtide has substantial literature as an innate immune activator and is an approved oncology adjunct in some regions. Research centers on NOD-like receptor signaling, macrophage activation, and downstream cytokine effects.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.